Brief: LifeMd To Offer Market-Leading Pricing For Glp-1 Medications Wegovy And Ozempic In Continued Collaboration With Novo Nordisk
17/11/2025 13:02
Nov 17 (Reuters) - LifeMD Inc LFMD.O: LIFEMD® TO OFFER MARKET-LEADING PRICING FOR GLP-1 MEDICATIONS WEGOVY® AND OZEMPIC® IN CONTINUED COLLABORATION WITH NOVO NORDISK LIFEMD INC - OFFERS GLP-1 MEDICATIONS AT $199 PER MONTH Source text: ID:nGNXbdRrtY Further company coverage: LFMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on LifeMD
See all newsLifeMD Inc reports results for the quarter ended June 30 - Earnings Summary
LifeMD Q2 revenue misses estimates as shift to branded GLP-1 therapies weighs
Brief: LifeMD Inc Q2 Revenue USD 47.3 Million Vs. IBES Estimate USD 49.2 Million
LifeMD Inc expected to post a loss of 15 cents a share - Earnings Preview
LifeMD Q1 revenue beats estimates on record telehealth subscriber additons